5 completed. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 3 | Completed 3 |
Follow Preleukemia: new trials by email Literature Review of Preleukemia trials Research Report on Preleukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS Decitabine, PDR001, MBG453 - Leukemia, Leukemia, Myeloid | Phase 1 | Completed | Novartis Pharmaceuticals | 241 | 2017-07-06 | 2025-05-18 |
| A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies Pelabresib, Ruxolitinib - Myelofibrosis, Leukemia, Myelocytic, Acute | Phase 1 / Phase 2 | Completed | Constellation Pharmaceuticals | 336 | 2014-07-16 | 2026-06-04 |
| A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia ARRY-520, KSP(Eg5) inhibitor; intravenous - Advanced MDS, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Pfizer | 36 | 2008-03-18 | 2021-02-08 |
| A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) lintuzumab, lenalidomide - Myelodysplastic Syndrome (MDS) | Phase 1 | Completed | Seagen Inc. | 13 | 2008-03-01 | 2011-10-12 |
| Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies Clofarabine, Melphalan, Campath - Advanced Hematologic Malignancies, Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 82 | 2006-03-01 | 2014-02-27 |
Hematologic Diseases (3) · Leukemia (3) · Leukemia, Myeloid, Acute (3) · Myelodysplastic Syndromes (3) · Bone Marrow Diseases (2) · Leukemia, Myeloid (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Precancerous Conditions (1) · Primary Myelofibrosis (1) · Thrombocythemia, Essential (1)
Hemic and Lymphatic Diseases (5) · Neoplasms (4) · Precancerous Conditions (4) · Neoplasms by Histologic Type (3) · Hematologic Diseases (2) · Leukemia, Myeloid (2) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Bone Marrow Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Hemorrhagic Disorders (1) · Leukemia (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Pathologic Processes (1)
Alemtuzumab (1) · Azacitidine (1) · CPI-0610 (1) · Clofarabine (1) · Decitabine (1) · Lenalidomide (1) · Melphalan (1) · Stem Cell Transplantation (1) · filanesib (1) · lintuzumab (1) · ruxolitinib (1) · sabatolimab (1) · spartalizumab (1)
Constellation Pharmaceuticals (1) · Novartis Pharmaceuticals (1) · Pfizer (1) · Seagen Inc. (1) · University of Chicago (1)
United States (5) · France (2) · Germany (2) · Netherlands (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Canada (1) · Finland (1) · Italy (1) · Poland (1) · Spain (1)
Andrew Artz, MD (1) · Eric Sievers, MD (1)
PMID 22139909, PMID 36881782, PMID 37530627, PMID 38259250
2016 (1), 2018 (1)